Nonetheless, the common theme is that GLP-1 RAs tend to push the microbiome in a direction associated with metabolic health (greater abundance of SCFA-producing and mucus-associated bacteria, lower abundance of pro-inflammatory organisms), although substantial changes may require prolonged therapy (56)
Not losing weight right away does not mean semaglutide isnt working
Supports long-term weight control and disease prevention
Key Findings: Primary composite endpoint at 1 year (death, nonfatal MI, stroke, major bleeding): 16.6% with ticagrelor 14.2% with prasugrel Not statistically significant (P=0.12) Ticagrelor showed numerically higher rates of ischemic and bleeding events, but none reached statistical significance
Direct evidence for the effect of glucagon on lean mass is seen from clinical situations of glucagon excess, in the glucagonoma syndrome (89)